Next Article in Journal
In Vitro Efficacy of Water-Soluble Mercaptopyridine-Substituted Oxotitanium (IV) Phthalocyanine Compounds in Photodynamic Therapy of Oral Squamous Cell Carcinoma
Previous Article in Journal
VPS26A as a Prognostic Biomarker and Therapeutic Target in Liver Hepatocellular Carcinoma: Insights from Comprehensive Bioinformatics Analysis
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
This is an early access version, the complete PDF, HTML, and XML versions will be available soon.
Article

The Effect of Extended Dissection of Lymph Nodes (D2plus) with Gastrectomy on the Clinical and Oncological Outcomes in Gastric Cancer Patients, Compared to a Standard Dissection (D2)

1
Department of Pediatric Surgery, Rambam Health Care Campus, 8 HaAliya HaShniya Street, Haifa 3109601, Israel
2
Department of Surgery, Tzafon Medical Center, Poriya 1528001, Israel
3
The Legacy Heritage Cancer Center, Dr. Larry Norton Institute, Soroka Medical Center, Ben-Gurion University, Beer Sheva 84105, Israel
4
Faculty of Health Sciences, Ben Gurion University of the Negev, Beer Sheva 84105, Israel
5
Department of Surgery, Bnai-Zion Medical Center, 47 Eliyahu Golomb Avenue, Haifa 3339419, Israel
6
Institute of Oncology, Bnai-Zion Medical Center, 47 Eliyahu Golomb Avenue, Haifa 3339419, Israel
7
The Ruth and Bruce Rappaport Faculty of Medicine, Technion, Israel Institute of Technology, 1 Efron Street, Haifa 3339101, Israel
*
Author to whom correspondence should be addressed.
These authors contributed equally to this work.
These authors contributed equally to this work.
Medicina 2025, 61(7), 1284; https://doi.org/10.3390/medicina61071284
Submission received: 19 May 2025 / Revised: 11 July 2025 / Accepted: 15 July 2025 / Published: 16 July 2025
(This article belongs to the Section Gastroenterology & Hepatology)

Abstract

Background and Objectives: Gastric cancer treatment of partial or complete gastrectomy includes lymph nodes dissection (D2) to remove microscopic lymph node metastases adjacent to the tumor. A more extensive approach, an extended dissection (D2plus) has recently been employed, which includes resection of the lymph nodes in the pancreatic and periportal areas. However, despite its potential benefits of longer survival for patients diagnosed with advanced cancer, there are increased risks due to surgical complications. The current study aims to examine the balance between clinical benefit and higher risks of the extended dissection approach versus standard dissection. Materials and Methods: This retrospective analysis of gastric cancer patients treated in Bnai-Zion medical center examined the survival rates, oncological outcomes, and complication rates according to medical records data files. Results: The D2plus group experienced increased postoperative complications rate (56% vs. 20.6% D2 group p = 0.005) with mean survival time, shorter than the D2 standard approach (2.07 years vs. 3.44 years p = 0.01). A higher number of lymph nodes was removed on average in the D2plus group (29.4 ± 11.2), but without statistical significance in comparison to the D2 group (22.6 ± 8.9, p = 0.013). D2plus patients had reduced disease recurrence rates (20% vs. 32.4% in D2 group p = 0.29). Weight loss of D2plus patients was noted for higher rates than the D2 group (40% vs. 17.6% p = 0.056. Conclusions: Our study provides preliminary insights into the comparison between D2 and D2plus dissection in a single-center Western cohort. However, significant baseline differences between groups, particularly age, gender, and histopathological characteristics, limit definitive conclusions. The findings should be interpreted as hypothesis-generating rather than practice-changing. Larger, prospective, multicenter studies with propensity score matching or randomized design are needed to definitively establish the optimal surgical approach for different patient subgroups.
Keywords: gastric cancer; surgery; dissection; lymph nodes; survival; recurrence; D2 lymphadenectomy; D2plus; extended; gastrectomy gastric cancer; surgery; dissection; lymph nodes; survival; recurrence; D2 lymphadenectomy; D2plus; extended; gastrectomy

Share and Cite

MDPI and ACS Style

Lazari, S.; Masalha, M.; Swaid, F.; Shalata, W.; Sroka, G.; Waked, W.; Agbarya, A. The Effect of Extended Dissection of Lymph Nodes (D2plus) with Gastrectomy on the Clinical and Oncological Outcomes in Gastric Cancer Patients, Compared to a Standard Dissection (D2). Medicina 2025, 61, 1284. https://doi.org/10.3390/medicina61071284

AMA Style

Lazari S, Masalha M, Swaid F, Shalata W, Sroka G, Waked W, Agbarya A. The Effect of Extended Dissection of Lymph Nodes (D2plus) with Gastrectomy on the Clinical and Oncological Outcomes in Gastric Cancer Patients, Compared to a Standard Dissection (D2). Medicina. 2025; 61(7):1284. https://doi.org/10.3390/medicina61071284

Chicago/Turabian Style

Lazari, Sahar, Muhammad Masalha, Forat Swaid, Walid Shalata, Gideon Sroka, Weam Waked, and Abed Agbarya. 2025. "The Effect of Extended Dissection of Lymph Nodes (D2plus) with Gastrectomy on the Clinical and Oncological Outcomes in Gastric Cancer Patients, Compared to a Standard Dissection (D2)" Medicina 61, no. 7: 1284. https://doi.org/10.3390/medicina61071284

APA Style

Lazari, S., Masalha, M., Swaid, F., Shalata, W., Sroka, G., Waked, W., & Agbarya, A. (2025). The Effect of Extended Dissection of Lymph Nodes (D2plus) with Gastrectomy on the Clinical and Oncological Outcomes in Gastric Cancer Patients, Compared to a Standard Dissection (D2). Medicina, 61(7), 1284. https://doi.org/10.3390/medicina61071284

Article Metrics

Back to TopTop